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study showed improvement with treatment and the other showed no change. All three studies measured brain
natriuretic peptide (BNP), a hormone released by the heart when it is under stress and a common marker of
severity of heart failure. Two studies found a significant decrease in BNP with treatment, and one study found
no change.
Conclusion: There is some evidence to suggest that vitamin D supplementation is beneficial earlier in the
disease process of CHF, but no evidence at this time to support that it is helpful in more elderly, advanced
disease patients. A larger randomized control trial is necessary to provide more evidence for or against vitamin
D supplementation in CHF.
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Abstract   
 
Background: Congestive heart failure (CHF) is a highly prevalent condition among aging 
adults, and a common cause of hospitalization in the United States. It is consequently a great 
financial burden. Many studies have shown a correlation between vitamin D deficiency and 
CHF, but little is known about the benefits, if any, of vitamin D supplementation in adults with 
CHF. 
 
Methods:  An exhaustive search was conducted using Medline-OVID, Medline-PubMed, and 
Web of Science using the keywords: vitamin D supplementation and heart failure. Relevant 
articles were assessed for quality using GRADE. 
 
Results:  Three trials were identified as meeting the inclusion criteria. The design of each study 
varied, as did the results. Two studies evaluated the 6-minute walk test (6MWT) as a measure of 
physical function. One study showed improvement with treatment and the other showed no 
change. All three studies measured brain natriuretic peptide (BNP), a hormone released by the 
heart when it is under stress and a common marker of severity of heart failure. Two studies found 
a significant decrease in BNP with treatment, and one study found no change. 
 
Conclusion:  There is some evidence to suggest that vitamin D supplementation is beneficial 
earlier in the disease process of CHF, but no evidence at this time to support that it is helpful in 
more elderly, advanced disease patients. A larger randomized control trial is necessary to provide 
more evidence for or against vitamin D supplementation in CHF. 
 
Keywords:  Vitamin D supplementation, Heart Failure 
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Vitamin D Supplementation as an Adjunct Therapy to 
Improve Physical Function and Decrease BNP in Adults with 
Congestive Heart Failure 
 
BACKGROUND 
 Congestive heart failure (CHF) is a highly prevalent disease and a common cause of 
hospitalization of adults in the United States. It is a disease causing both morbidity and mortality 
in elderly patients. Heart failure is often debilitating, and CHF patients experience both a 
decrease in heart function and physical function as the disease progresses. Increased filling 
pressures put extra stress on the heart, causing the heart muscle to hypertrophy and eventually 
stretch. This leads to a decline in the heart’s ability to contract, relax, or both. The result is a 
back up of fluid into the pulmonary vasculature which leaks into the lungs, causing shortness of 
breath, especially when the patient lies flat. Fluid can also accumulate in the periphery as the 
systemic circulation is unable to flow well into the dysfunctional heart. Patients often require 
frequent follow up with their primary care providers to adjust medical therapy as heart failure 
progresses. These patients also are frequently admitted to the hospital due to CHF exacerbations, 
and can require several days of inpatient care to be medically controlled. As such, it is a 
significant financial burden.  
Multiple studies have shown that vitamin D deficiency is common in CHF patients, but 
there is still uncertainty as to the full effects of vitamin D supplementation on CHF.1, 2 
Researchers are still unsure as to the cause of this deficiency, whether it is the result of CHF or a 
possible contributor to the disease. Vitamin D deficiency is a predictor of mortality in patients 
with heart failure, and supplementation of vitamin D is associated with decreased mortality.2 
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Vitamin D is a cheap, readily accessible, and safe supplement. It would provide a simple option 
for adjunct therapy if found to be of benefit in CHF patients. Any potential treatment for CHF 
would have to show benefits in physical function, cardiac function, or both.  A good marker of 
physical function is the 6-minute walk test (6MWT), which measures how many meters a patient 
can walk on a flat surface in 6 minutes.  Cardiac function is often trended by measuring brain 
natriuretic peptide (BNP), a hormone released from the walls of the heart when it is stretched and 
under stress.  Levels of this hormone will increase in patients with worsening CHF.  Both of 
these tests quantify changes in CHF.  Any therapy showing improvement in the disease process 
of CHF would potentially equate to slowed disease progression, increased cardiac and physical 
function, and fewer hospitalizations. With this possibility in mind, analyzing whether vitamin D 
supplementation can improve function in adults with CHF is an important research question. 
METHODS 
 An exhaustive literature search of Medline-OVID, Medline-PubMed, and Web of Science 
using the terms “vitamin D supplementation” and “heart failure” was undertaken. Preliminary 
search results were then limited to clinical trials, English language only, and human subjects. 
Studies were eligible for inclusion if they evaluated adult patients with a current diagnosis of 
CHF, treated patients with oral vitamin D supplementation for a minimum of 12 weeks, and 
measured BNP levels, the 6MWT, or both as outcomes. One study was excluded due to a short 
duration of therapy and follow up. Relevant articles were assessed for quality using GRADE.3 
RESULTS 
 The search of literature resulted in three trials addressing the question and meeting 
inclusion criteria. These studies focused on several different aspects of CHF and used various 
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markers of disease, but all three studies4, 5, 6 measured brain natriuretic peptide (BNP) and two of 
the studies 4, 6 measured the 6-minute walk test (6MWT) in patients. All three studies4, 5, 6 looked 
at adults, although the age range of each study varied considerably. See Table I. 
Amin et al 
 This study4 examined 100 consecutive patients with the diagnosis of CHF presenting to 
the Heart Failure and Transplant Clinic of Rajaei Cardiovascular, Medical and Research Center, 
in Tehran, Iran. Patients were recruited in September 2010 and February 2012, and were all 
required to be at least 15 years old to be included in the trial. The study consisted of 73 men and 
27 women, with an average age of 45.25±15.53 years. All patients were on optimal medical 
treatment for heart failure according to the latest guidelines for medical management, for at least 
3 months prior to the study, and remained on the same medical regimen during the duration of 
the study.4  
 Patients were assessed at baseline for NYHA functional class as determined by the same 
investigator while observing the patient perform activities of daily living. Baseline NYHA class 
evaluation yielded 3% of patients in class I, 45% of patients in class II, and 52% of patients in 
class III. The 6MWT, proBNP, and serum 25 (OH) D levels were all collected at baseline, as 
well as echocardiographic data. Patients were categorized into normal, insufficient, and deficient 
groups based on vitamin D levels, with 25 (OH) D levels of >30 ng/ml, 20-29.9 ng/ml, and <20 
ng/ml respectively. Patients with insufficient or deficient levels were given oral vitamin D3 for 4 
months. This was administered at a dose of 50 000 IU every week for 8 weeks, then 50 000 IU 
every month for 2 months. All patients were evaluated again at the completion of treatment.4  
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 At baseline, 25 (OH) D levels had no statistically significant correlation with NYHA 
functional class, proBNP, or 6MWT. However, NYHA class was significantly associated with 
6MWT, and with proBNP level. After 12 weeks of supplementation, the mean 25 (OH) D level 
increased by 41.86 ng/ml for a mean of 54.49±18.01 ng/ml (P<.001). NYHA functional class 
improved significantly (P<.001), as did the 6MWT (P<.001). There was also a significant drop in 
proBNP hormone levels by 827.32 pg/ml (P<.001). See Table II. This data could not be 
compared to the untreated group with sufficient 25 (OH) D levels at baseline, as this group only 
had 6 subjects and was too small for a quality comparison.4  
 The authors noted that their study was successful in raising the average concentration of 
vitamin D in their patients to the optimum level. They also recognized that they included a 
younger population in their study, and that this may contribute to the significant improvement 
seen in their patients as intervention earlier in the disease process may be more beneficial. They 
also noted that they used vitamin D3, which has a longer half-life and results in greater peak 
levels of vitamin D compared to other oral forms of the vitamin. There were no losses due to 
follow up.  However, the authors also acknowledged that their study had a small sample size and 
had no placebo control group to offer comparison.4  
Schleithoff et al 
 This double-blind, randomized, placebo-controlled trial5 evaluated 123 CHF patients 
from the Heart and Diabetes Center Nordrhein-Westfalen, Germany.  Patients (102 men and 21 
women) were recruited between March 2002 and April 2003.  Most patients were in their 50s or 
early 60s, and all participants had a NYHA functional class of II or higher.5  
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 Patients were randomly assigned in a double-blind manner by a computer generated 
random number list to the intervention group or the control group. The 61 patients in the 
intervention group were given 2000 IU of vitamin D3 daily, and the 62 patients in the control 
group were given a placebo daily. Both groups were given 500 mg of calcium daily to ensure 
patients received the recommended intake for calcium. Therapy lasted for a period of nine 
months. Baseline levels of proBNP were measured along with other biochemical markers and 
hemodynamic variables. Patient compliance was documented with bottle counts at each visit. 
Patients also completed a validated food record the day before each visit to estimate dietary 
intake of vitamin D and calcium. Thirty patients did not complete the study, 25 of them due to a 
marked worsening of their health, and the others were excluded due to noncompliance.5 
 There was no statistical difference between the groups at baseline with the exception of 
lower interleukin-10 serum levels in the treatment group. After therapy was completed, all 
measurements were repeated. Vitamin D supplementation increased median 25 (OH) D levels by 
26.8 ng/ml for a median of 42 ng/ml (P=.001). There was no significant change in proBNP with 
vitamin D supplementation. See Table III.5  
 The authors acknowledged that the increase in serum 25 (OH) D levels in the treatment 
group was likely below optimal levels, and that higher doses of supplementation resulting in 
higher serum vitamin D levels would probably result in additional improvement in CHF patients. 
The authors also noted that there was a relatively high dropout rate in their study. They also 
recognized that calcium supplementation in both groups may have contributed to changes in 
cardiac function, but they pointed out that dietary calcium intake in their patients was below the 
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recommended level, and so recommended calcium levels were only achieved with the 
supplementation provided by the study.5  
Witham et al 
 This double-blinded, randomized control trial6 evaluated patients age 70 or older with a 
clinical diagnosis of heart failure, NYHA class II or III. All participants were required to have a 
25 (OH) D level <20 ng/ml to be included. Patients were recruited from primary and secondary 
care clinics in areas of Scotland from June 2005 to October 2008. All patients were of white 
European origin. A total of 105 patients passed screening to participate in the study.6  
 Patients were randomized by a computer into the intervention group (53 patients) or the 
control group (52 patients) and allocation was concealed from all parties. Baseline 
measurements, including the 6MWT and BNP were recorded prior to any intervention. The 
treatment group received 100 000 IU of vitamin D2 at this baseline visit, and again at 10 weeks. 
The control group received a placebo at both of these visits. Administration of each dose was 
supervised to ensure compliance. Outcomes were then measured again at 10 weeks and 20 
weeks. During the trial, a total of 9 patients were lost to follow up due to death, illness, protocol 
violation, and moving away.  There were 48 patients in each group at the end of the study.6 
 The groups were statistically different at baseline, so the difference in change in 
outcomes at 20 weeks was adjusted for baseline variables. If data was missing for the 6MWT, it 
was assumed that the patient could not walk and therefore had a 6MWT result of 0. Failure to 
perform the 6MWT was due to death, illness, or poor health preventing the patient from being 
able to stand and walk without assistance. In the treatment group, the increase in 25 (OH) D 
levels was statistically significant (P<.001) but the mean level at 10 weeks and 20 weeks never 
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rose above 30 ng/ml. There was no statistically significant change in the 6MWT between the two 
groups. However, BNP decreased significantly in the treatment group compared with the control 
group by 10 weeks (P=0.04) and continued to drop by 20 weeks (P=0.05). See Table IV.6 
 The authors of this study acknowledged that there were specific strengths and weaknesses 
in this trial. There were narrow confidence intervals around the change in the 6MWT, making it 
unlikely that a clinically significant effect was missed. But a major limitation of this study is that 
it used vitamin D2 and not vitamin D3 for oral supplementation. Vitamin D3 has a longer half-
life and results in greater peak levels of vitamin D, making it the preferred oral vitamin D 
supplementation. However, only vitamin D2 was available at the time of this study. The authors 
also note that higher or more frequent doses of vitamin D may be required to see benefits in CHF 
patients, and intervention earlier in the disease process may also result in greater effects.6 
DISCUSSION 
 Oral vitamin D is a cheap, safe, and well tolerated supplement. Some studies report that 
up to 50% of the US population is vitamin D deficient.7 This deficiency is even more common 
among CHF patients.8 Because of this, the threshold for recommending this supplement to 
patients is likely very low for most clinicians. The Amin et al study4 seems to indicate that 
vitamin D supplementation is likely of benefit in younger CHF patients that are early in disease 
progression. However, the dosing must be sufficient to raise serum vitamin D levels to an 
optimal level, 30 ng/ml or higher, and the treatment likely needs to be weekly or more frequent 
dosing and long term.4, 5, 6 Moreover, vitamin D3 supplementation is preferable over vitamin D2 
based on a meta-analysis that concluded such.9 Vitamin D supplementation appears to be less 
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effective in elderly CHF patients, but until there are more studies evaluating the effects of 
vitamin D3 supplementation long term there is insufficient evidence to be sure.  
 
 Each of these studies had limitations. All of the studies had a small sample size around 
100 patients. Amin et al4 lacked a placebo treated control group, and therefore had no 
comparison for the intervention group. This raises the concern that there may be confounding 
variables affecting the results that the authors did not recognize due to this lack of comparison. 
Schleithoff et al5 and Witham et al6 patients had suboptimal vitamin D levels at the end of the 
study. As a result, the effects of optimal vitamin D levels in these patients are unknown, and 
there may have been additional benefits with high levels of vitamin D. Witham et al6 had the 
significant limitation of using vitamin D2 instead of vitamin D3, which is considered to be the 
more beneficial oral vitamin D supplementation. The supplementation was given in two large 
bolus doses, whereas a more frequent and consistent dosing of vitamin D would likely be more 
beneficial than an intermittent bolus.10 This study also excluded heart failure patients with 
preserved systolic function, a characteristic common in many heart failure patients.11 This 
prevents the results from being applied to certain types of CHF patients. It should also be noted 
that this study used a more elderly CHF population, but intervention at a younger age would 
likely prove to be of greater benefit. 
 
 The assumption is that the earlier the intervention and the more frequent the dosing of 
vitamin D, the more likely the patient will experience the benefits of supplementation. Vitamin D 
has numerous known health benefits, such as improvement in cognition12, liver disease13, and 
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bone health.14 It also has tremendous potential in improving CHF via various biochemical 
markers such as parathyroid hormone, tumor necrosis factor, and interleukin-10.5 
 
 Based on these results, the overall quality of evidence is very low and future research 
conducted should include a larger, randomized, double blinded placebo controlled trial using 
vitamin D3 supplementation in younger CHF patients. It would be imperative to use high, 
frequent doses of vitamin D3 to ensure optimal levels of serum 25 (OH) D after intervention. 
Using 6MWT as a measure of physical function, and BNP as a measure of cardiac function 
would also be recommended. This would provide more conclusive evidence as to whether or not 
vitamin D supplementation can improve physical function and cardiac function in CHF. 
CONCLUSION 
 Research on vitamin D supplementation in CHF patients is still inconclusive. There is 
some evidence that vitamin D3 is of benefit in younger patients with CHF, but it should be 
supplemented at an adequate dose to meet optimal levels for the patient to experience benefits. 
There is currently no evidence that is it helpful in elderly CHF patients, but there is a lack of 
definitive research for or against supplementing in this population at this time. However, the lack 
of research does not mean that there is no use for supplementation in these patients, and there is 
still great potential for improvement of cardiac function and hemodynamic variables in this 
population. There is a great need for a larger randomized control trial to better evaluate the 
benefits, if any, of vitamin D3 supplementation in CHF patients. 
15 
 
References 
1. Liu L. Chen M. Hankins SR. Nunez AE. Watson RA. Weinstock PJ. Newschaffer CJ. Eisen 
HJ. Drexel Cardiovascular Health Collaborative Education, Research,and Evaluation Group. 
Serum 25-hydroxyvitamin D concentration and mortality from heart failure and cardiovascular 
disease, and premature mortality from all-cause in United States adults. Am J Cardiol. 
2012;110:834-839.  
2. Gotsman I, Shauer A, Zwas DR, et al. Vitamin D deficiency is a predictor of reduced survival 
in patients with heart failure; vitamin D supplementation improves outcome. Eur J Heart Fail. 
2012;14:357-366.  
3. http://www.gradeworkinggroup.org/ 
4. Amin A, Minaee S, Chitsazan M, Naderi N, Taghavi S, Ardeshiri M. Can vitamin D 
supplementation improve the severity of congestive heart failure?. Congest Heart Fail. 
2013;19:E22-8.  
5. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D 
supplementation improves cytokine profiles in patients with congestive heart failure: a double-
blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83:754-759.  
6. Witham MD, Crighton LJ, Gillespie ND, Struthers AD, McMurdo ME. The effects of vitamin 
D supplementation on physical function and quality of life in older patients with heart failure: a 
randomized controlled trial. Circ Heart fail. 2010;3:195-201.  
16 
 
7. Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an important, 
common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol. 2008;52:1949-1956.  
8. Agarwal M, Phan A, Willix R,Jr, Barber M, Schwarz ER. Is vitamin D deficiency associated 
with heart failure? A review of current evidence. J Cardiovasc Pharmacol Ther. 2011;16:354-
363.  
9. Tripkovic L, Lambert H, Hart K, et al: Comparison of vitamin D2 and vitamin D3 
supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-
analysis. Am J Clin Nutr 2012. 
10. Begg GA, Cleland JG, Witte KK. Letter by Begg et al regarding article, "The effects of 
vitamin d supplementation on physical function and quality of life in older heart failure patients: 
a randomized controlled trial". Circ Heart fail. 2010;3:e24.  
11. Levitan EB, Judd SE. Can vitamin D supplementation improve physical function and quality 
of life in older patients with heart failure?. Circ Heart fail. 2010;3:183-184.  
12. Skalska A, Galas A, Grodzicki T. 25-hydroxyvitamin D and physical and cognitive 
performance in older people with chronic conditions. Pol Arch Med Wewn. 2012;122:162-169.  
13. Han YP, Kong M, Zheng S, et al. Vitamin D in liver diseases: from mechanisms to clinical 
trials. J Gastroenterol Hepatol. 2013;28:49-55. 
14. Cauley JA. The Women's Health Initiative: Hormone Therapy and Calcium/Vitamin D 
supplementation trials. Curr osteoporos rep. 2013;11:171-178.  
17 
 
Table I. Characteristics of Reviewed Studies 
aLack of allocation concealment, lack of blinding and no control group 
bSmall sample size 
cSignificant loss to follow up 
d Intervention different from available evidence 
eBNP is not the primary outcome in this study 
 
Quality Assessment  
 Downgrade Criteria 
Quality 
Study Design Limitations Inconsistency Indirectness Imprecision 
Publication 
bias likely 
Amin et al4  RCT 
Very serious 
limitationsa 
No serious 
inconsistencies 
No serious 
indirectness 
Serious imprecisionb No bias likely Very Low 
Schleithoff et 
al5 
RCT 
No serious 
limitations 
No serious 
inconsistencies 
No serious 
indirectness 
Very serious 
imprecisionb,c 
No bias likely Low 
Witham et al6 RCT 
No serious 
limitations 
No serious 
inconsistencies 
Serious 
indirectnessd,e 
Serious imprecisionb No bias likely Low 
18 
 
Table II. Amin et al4 
 Baseline Post intervention 
Outcome 
Intervention 
(n= 94) 
Control 
(n=6) 
Intervention Control 
6MWT (m) 363±77 394±61 393±88 407±72 
proBNP (pg/ml) 2508.60±1867.99 1125.16±696.62 1681.28±1181.68 1022.82±726.82 
25 (OH) D (ng/ml) 12.63±7.60 41.33±15.95 54.49±18.01 47.72±13.82 
aMean±Standard Deviation 
bP value unavailable due to small control group 
 
Table III. Schleithoff et al5 
 Baseline Post Intervention  
Outcome Intervention (n=42) Control (n=51) Intervention Control P value 
proBNP (pg/ml) 721 (444,1140) 859 (180,1869) 730 (345, 1417) 909 (69, 2305) 0.457 
25 (OH) D (ng/ml) 14.4 (11.5, 22.1) 15.3 (12.7, 22.8) 41.2 (20.7, 57.2) 18.9 (9.9, 31.3) 0.001 
aMedian (Interquartile ranges) 
 
Table IV. Witham et al6 
 Baseline Post intervention 
Outcome 
Treatment 
(n= 53) 
Control 
(n=52) 
Treatment Control 
6MWT (m)a 249±116 237±108 246.9±155.9 240.5±144.5 
BNP (pg/ml)b 142 (290) 168 (274) 127 (450) 205 (427) 
25 (OH) D (ng/ml)a 8.21±3.57 9.50±4.01 16.02±9.14 10.02±9.38 
aMean±Standard Deviation 
bMedian (Interquartile Range) 
 
 
 
